AzTrials
AzTrials

MyopiaNCT02193178

Multicenter Dispensing Study of Biofinity Toric Made-To-Order Lenses in Extended Power Ranges

A study testing comfilcon A Toric in people with Myopia and Astigmatism, run by CooperVision, Inc. at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study hypothesis is that the Biofinity Toric XR lenses will perform as well as or better than the participants' habitual contact lenses. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Myopia, Astigmatism
What is being tested?
comfilcon A Toric
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
2 sitesUnited States
Study dates
Jul 2014to Apr 2016
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Has had an oculo-visual examination in the last two years
  • Is at least 18 years of age and has full legal capacity to volunteer
  • Has read and understood the information consent letter
  • Is willing and able to follow instructions and maintain the appointment schedule
  • Is correctable to a visual acuity of 20/50 or better (in at least one eye)
  • Currently wears soft toric contact lenses in both eyes
Show all 14Show fewer
  • Subject contact lens prescription must fall under one of the contact lens power ranges for at least one eye:
  • -20.00D to -10.50D spherical powers and cylinder powers from - 0.75 to -2.25
  • +8.50D to +20.00D spherical powers and cylinder powers from - 0.75 to -2.25
  • -20.00D to -6.50D spherical powers and cylinder powers from -2.75 to -5.75
  • -6.00D to +6.00D spherical powers and cylinder powers from -2.75 to -5.75
  • +6.50D to +20.00D spherical powers and cylinder powers from-2.75 to -5.75
  • Has clear corneas and no active ocular disease
  • Demonstrates an acceptable fit with the study lenses

Who cannot join

  • Has never worn contact lenses before;
  • Has any systemic disease affecting ocular health;
  • Is using any systemic or topical medications that will affect ocular health;
  • Has any ocular pathology or abnormality that would affect the wearing of contact lenses;
  • Has undergone corneal refractive surgery;
  • Is participating in any other type of eye related clinical or research study.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Clinical Optics Research Lab (CORL) Indiana University School of Optometry, Indiana University

    Bloomington, Indiana, 47405

  • Texas Eye Research and Technology Center (TERTC) College of Optometry, University of Houston

    Houston, Texas, 77204

Other trials in United States

About this study

The study hypothesis is that the Biofinity Toric XR lenses will perform as well as or better than the participants' habitual contact lenses.

Read the detailed description

The study hypothesis is that the Biofinity Toric XR lenses will perform as well as or better than the participants' habitual contact lenses. Further, that a minimum of 80% of those enrolled will complete 2 weeks of lens wear with no contraindication to continue.

Conditions
Myopia, Astigmatism
Being tested
comfilcon A Toric
Medical subject headings
Myopia, Astigmatism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • comfilcon A ToricDevice

    Also called Biofinity

    Contact lenses

Study groups in NCT02193178
Study groupRoleWhat they receive
comfilcon A toricExperimentalParticipants are habitual toric lens wearers and will be fitted with comfilcon A toric lenses.
Receives: Device: comfilcon A Toric

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Comfort

    Subjective ratings for overall comfort for habitual lenses assessed 2 weeks prior to baseline and for comfilcon A lenses assessed at baseline and 2 weeks post baseline. Scale 0-100, 0=cannot be worn, causes pain, and 100=cannot be felt ever.

    Measured: 2 weeks prior to baseline, Baseline, 2 weeks post baseline

  2. Overall Vision

    Subjective ratings for overall vision for habitual lenses assessed 2 weeks prior to baseline and vision for comfilcon A assessed at baseline and 2 weeks post.Scale 0-100, 0=Extremely poor vision all of the time, cannot function, 100=Excellent vision all of the time.

    Measured: 2 weeks prior to baseline, Baseline, 2 weeks post

  3. Handling

    Subjective ratings for handling for habitual lenses assessed 2 weeks prior to baseline and handling for comfilcon A assessed at baseline and 2 weeks post baseline. Scale 0-100, 0=Very difficult, 100=Very easy

    Measured: 2 weeks prior to baseline, Baseline, 2 weeks post baseline

  4. Overall Satisfaction

    Subjective ratings for overall satisfaction for habitual lenses assessed 2 weeks prior to baseline and overall satisfaction for comfilcon A assessed at baseline and 2 weeks post baseline. Scale 0-100, 0=Extremely dissatisfied, 100=Extremely satisfied.

    Measured: 2 weeks prior to baseline, Baseline, 2 weeks post baseline

  5. Lens Fit - Rotation

    Lens Fit (rotation) for habitual lenses were assessed 2 weeks prior to baseline and then refitted with comfilcon A lenses. After refitting with comfilcon A, lens fit rotation was assessed at baseline and 2 weeks. Lens rotation was measured within 10 degrees of the desired 6 o'clock position. Scale 0-180 degrees, 0=no rotation, 180=max rotation.

    Measured: 2 weeks prior to baseline, Baseline, 2 weeks post baseline

  6. Lens Fit - Overall Stability

    Lens Fit (stability) for habitual lenses assessed 2 weeks prior to baseline and then refitted with comfilcon A lenses. After refitting with comfilcon A lenses, stability was assessed at baseline and 2 weeks. Scale 0-4, 0=Totally unstable, can't be worn to provide acceptable vision correction for an astigmatism, 4=Excellent orientation and optimum rotational recovery and stability

    Measured: 2 weeks prior to baseline, Baseline, 2 weeks post baseline

  7. Lens Fit Acceptance

    General lens fit acceptance for habitual lenses assessed 2 weeks prior to baseline and refitted with comfilcon A lenses, which were assessed at baseline and at 2 weeks. (Scale 0-4, 0=Can't be worn; 4=Optimum)

    Measured: 2 weeks prior to baseline, Baseline, 2 weeks post baseline

  8. Anterior Ocular Health - Palpebral Hyperemia and Roughness

    Palpebral hyperemia and roughness for comfilcon A lenses assessed at baseline and 2 weeks. Scale 0-4, 0=None, 4=Severe

    Measured: Baseline and 2 weeks

  9. Anterior Ocular Health - Bulbar and Limbal Redness

    Bulbar and limbal redness for comfilcon A lenses assessed at baseline and 2 weeks. Scale 0-4, 0=None; 4=Severe injection

    Measured: Baseline and 2 weeks

  10. Anterior Ocular Health - Corneal Staining

    Corneal staining for comfilcon A lenses assessed at baseline and 2 weeks. Scale 0-4, 0=No staining; 4= >45% of area

    Measured: Baseline and 2 weeks

  11. Anterior Ocular Health - Conjunctival Staining and Indentation

    Conjunctival staining and indentation for comfilcon A lenses assessed at baseline and 2 weeks. Conjuctival staining scale 0-4, 0=None, 4=Severe

    Measured: Baseline and 2 weeks

  12. Visual Acuity

    Visual acuity for habitual lenses assessed 2 weeks prior to baseline and for comfilcon A assessed at baseline and 2 weeks post baseline using logMAR.

    Measured: 2 weeks prior to baseline, Baseline, 2 weeks post baseline

  13. Subjective Preference - Comfort

    Subjective preference for comfort between habitual lenses and comfilcon A lenses assessed at baseline and 2 weeks. Preference choices: Prefers comfilcon A lenses, No preference, Prefers habitual lenses

    Measured: Baseline and 2 weeks

  14. Preference - Vision

    Subjective preference for vision between habitual lenses and comfilcon A lenses assessed at baseline and 2 weeks. Preference choices: Prefers comfilcon A lenses, No preference, Prefers habitual lenses

    Measured: Baseline and 2 weeks

  15. Preference - Handling

    Subjective preference for handling between habitual lenses and comfilcon A lenses assessed at baseline and 2 weeks. Preference choices: Prefers comfilcon A lenses, No preference, Prefers habitual lenses

    Measured: Baseline and 2 weeks

  16. Overall Preference

    Overall subjective preference between habitual lenses and comfilcon A lenses assessed at baseline and 2 weeks. Preference choices: Prefers comfilcon A lenses, No preference, Prefers habitual lenses

    Measured: Baseline and 2 weeks

  17. Investigator Acceptability

    Investigator's preference on acceptability of refitting subjects in to comfilcon A lens based on lens performance assessed at baseline and 2 weeks.Scale 1-5, 1=Strongly agree, 5=Strongly disagree.

    Measured: Baseline and 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2014 (estimated)
  2. Study startJul 2014
  3. Primary completionApr 2016
  4. Study completionApr 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02193178
Sponsor's protocol ID
CV-14-05
Status last verified
Jul 2020
First submitted
15 Jul 2014
Last updated
29 Jul 2020
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing comfilcon A Toric in people with Myopia and Astigmatism, run by CooperVision, Inc. at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Feb 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Comfort (time frame: 2 weeks prior to baseline, Baseline, 2 weeks post baseline). The study lists 17 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in